Premium
Comparative effectiveness of once‐weekly glucagon‐like peptide‐1 receptor agonists with regard to 6‐month glycaemic control and weight outcomes in patients with type 2 diabetes
Author(s) -
Unni Sudhir,
Wittbrodt Eric,
Ma Junjie,
Schauerhamer Marisa,
Hurd Jeff,
RuizNegrón Natalia,
McAdamMarx Carrie
Publication year - 2018
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13107
Subject(s) - dulaglutide , exenatide , medicine , type 2 diabetes , glucagon like peptide 1 receptor , weight loss , cohort , endocrinology , diabetes mellitus , obesity , receptor , agonist
A retrospective cohort study was conducted in patients with type 2 diabetes in an electronic medical record database to compare real‐world, 6‐month glycated haemoglobin (HbA1c) and weight outcomes for exenatide once weekly with those for dulaglutide and albiglutide. The study included 2465 patients: exenatide once weekly, n = 2133; dulaglutide, n = 201; and albiglutide, n = 131. The overall mean (standard deviation [s.d.]) age was 60 (11) years and 54% were men; neither differed among the comparison groups. The mean (s.d.) baseline HbA1c was similar in the exenatide once‐weekly (8.3 [1.7]%) and dulaglutide groups (8.5 [1.5]%; P = .165), but higher in the albiglutide group (8.7 [1.7]%; P < .001). The overall mean (s.d.) HbA1c change was −0.5 (1.5)% ( P < .001) and this did not differ among the comparison groups in either adjusted or unadjusted analyses. The mean (s.d.) weight change was −1.4 (4.7) kg for exenatide once weekly and −1.6 (3.7) kg for albiglutide ( P = .579), but was greater for dulaglutide, at −2.7 (5.7) kg ( P = .001). Outcomes were similar in subsets of insulin‐naive patients with baseline HbA1c ≥7.0% or ≥9.0%. All agents significantly reduced HbA1c at 6 months, with no significant differences among agents or according to baseline HbA1c in insulin‐naive subgroups.